Antibody Contract Manufacturing Global Market Report 2024

The antibody contract manufacturing market size has grown rapidly in recent years. It will grow from $12.84 billion in 2023 to $14.71 billion in 2024 at a compound annual growth rate (CAGR) of 14.6%. The expansion observed in the historical period can be attributed to a heightened demand for monoclonal antibodies, a shift towards personalized medicine, efforts in cost optimization, adherence to stringent regulatory requirements, and the globalization of biologics.

The antibody contract manufacturing market size is expected to see rapid growth in the next few years. It will grow to $25.27 billion in 2028 at a compound annual growth rate (CAGR) of 14.5%. The anticipated growth in the forecast period can be ascribed to the escalation in research and development (R&D) spending, the expansion of bispecific and multispecific antibodies, the rise of antibody-drug conjugates (ADCs), the augmentation of healthcare infrastructure, and the proliferation of government initiatives. Noteworthy trends in the forecast period encompass digitalization and data analytics, advancements in upstream technologies, innovative downstream processing techniques, sustainability initiatives, and the integration of contract development and manufacturing (CDMO).

The anticipated rise in the number of clinical trials is poised to drive the growth of the antibody contract manufacturing market in the coming years. Clinical trials, which involve research studies conducted with human participants to assess the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures, are witnessing an increase in the utilization of antibody-based therapeutics or diagnostics. This surge accentuates the demand for high-quality antibodies to ensure a timely and compliant supply for clinical trials. According to ClinicalTrials.gov's May 2023 data, the number of registered clinical trial studies globally increased from 399,499 in 2022 to 437,533 in 2023, with around 53% of these studies registered outside the United States. Hence, the growing number of clinical trials is a key driver behind the expansion of the antibody contract manufacturing market.

The expected growth in the prevalence of chronic diseases is set to propel the antibody contract manufacturing market forward. Chronic diseases, characterized by their persistent and often progressive nature, require therapeutic antibodies for treatment. Antibody contract manufacturing plays a vital role in producing these therapeutic antibodies designed to target specific proteins or cells associated with chronic conditions, offering targeted and personalized treatment. With the U.S. population aged 50 and above projected to increase by 61.11% by 2050, and the prevalence of chronic diseases in this demographic nearly doubling, from 71.522 million in 2020 to an estimated 142.66 million by 2050, the demand for antibody contract manufacturing is expected to rise significantly.

Technological advancements represent a notable trend in the antibody contract manufacturing market, with major companies adopting innovative technologies to maintain their market positions. For example, in October 2021, Merck KGaA introduced ChetoSensar, a groundbreaking technology designed to address solubility challenges in antibody-drug conjugates (ADCs). Leveraging their expertise in contract development manufacturing, Merck KGaA aims to enhance the solubility of high-potency active pharmaceutical ingredients (HPAPIs) and improve the effectiveness of next-generation antibody-drug conjugates through the innovative ChetoSensar technology.

Major companies in the antibody contract manufacturing market are focused on developing innovative solutions such as bispecific antibody platforms. These platforms play a pivotal role in the development of bispecific antibodies, utilizing scientific and technological approaches to create specialized antibodies. For instance, in September 2022, Samsung Biologics launched 'S-DUAL' and 'DEVELOPICK.' S-DUAL, a high-yield bispecific antibody platform, boasts a remarkable 99% success rate in chain pairing, optimizing manufacturing ease and achieving elevated titer and purity. DEVELOPICK, a rapid accessibility platform, enables the screening of molecules in early development, identifying candidates with optimal potential for progression to Investigational New Drug (IND) and Biological License Application (BLA). This comprehensive risk assessment platform empowers clients to evaluate drug candidates efficiently.

In April 2022, Asahi Kasei Medical Co., Ltd. acquired Bionova Scientific LLC for an undisclosed amount. This strategic acquisition expanded Asahi Kasei Medical's bioprocess business by incorporating a biopharmaceutical CDMO (contract development and manufacturing organization). Bionova Scientific LLC, a U.S.-based CDMO, specializes in developing and manufacturing recombinant protein products, including antibodies.

Major companies operating in the antibody contract manufacturing market report are AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim Biopharmaceuticals GmbH, Fujifilm Holdings Corporation, Eurofins Scientific SE, Lonza Group AG, Labcorp Drug Development, Catalent Inc., Charles River Laboratories International Inc., Merck KGaA, Samsung Biologics Co. Ltd., Wuxi Biologics Cayman Inc, Pierre Fabre Group, Siegfried Holding AG, Recipharm AB, Emergent BioSolutions Inc., Aenova Group, Cambrex Corporation, Aldevron LLC, Novasep Holding SAS, Synthon, KBI Biopharma Inc., Nitto Avecia Pharma Services Inc., Cytovance Biologics Inc., AGC Biologics S.p.A.

North America was the largest region in the antibody contract manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody contract manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antibody contract manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The antibody contract manufacturing market includes revenues earned by entities by providing services such as cell line development, process optimization, and the manufacturing of clinical trial materials. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.